Company to highlight next-generation, novel programmed T cell therapies in development for hematological and solid tumor indications
Program and webcast to begin at 8:00 am ET
LONDON, March 07, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer, today announced that the company will host an R&D Day in New York City on March 26, 2019.
The program will provide insights into the science behind tumor defense mechanisms and the company’s novel programmed T cell therapy programs in development utilizing targeted, modular approaches designed to address these mechanisms. The featured speaker, Dr. Samir N. Khleif, MD, Professor of Oncology, Director of Jeannie and Tony Loop Immuno-Oncology Laboratory, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, will discuss his work focused on understanding mechanisms through which the immune system and cancer cells interact as well as challenges and opportunities in addressing the hostile tumor microenvironment.
Dr. Christian Itin, chairman and chief executive officer and Dr. Martin Pule, founder and chief scientific officer of Autolus and Clinical Senior Lecturer at University College London Cancer Institute, along with other members of Autolus’ management, will highlight progress made in the company’s clinical portfolio and discuss the future direction for additional product candidates in hematological and solid tumors.
The event is open to institutional investors and sell side analysts. To attend in person, please notify the Investor Relations contact noted below in this press release. A live video webcast of the event will be available beginning at 8:00 am ET on the Events section of Autolus’ website. An archived replay will be available on the website for one year.
About Autolus Therapeutics plc
Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. For more information please visit www.autolus.com.
Investor relations contact:
Susan A. Noonan
S.A. Noonan Communications
Vice President, Corporate Affairs and Communications, Autolus
Media contact (UK):
+44 (0) 7818 430877